Four pharma firms – Cipla, Jubilant Life Sciences, Hetero and Mylan – have entered into non-exclusive licensing agreements with drug major Gilead Sciences for manufacturing and distribution of remdesivir, a potential therapy for COVID-19. The medicine has been issued an Emergency Use Authorization (EUA) by the United States Food and Drug Administration (FDA) to treat … Continue reading Cipla, Jubilant Life, Hetero, Mylan ink licensing pact with Gilead for remdesivir